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Abstract: The control of rabies, where successful, is built on a
One Health paradigm. In many instances, the control of human
disease rests on programs designed to limit canine rabies. Early
rabies programs were not only One Health based but simultane-
ously helped deﬁne, develop and operationalize the concept of
One Health. The development of rabies control programs in the
United States will be examined with a particular emphasis on the
development of different elements of the One Health paradigm. A
review of One Health based, creative approaches used by the early
rabies programs and how these programs provided a template for
other creative zoonotic and non-zoonotic control programs will
be described. Selected other successful rabies control programs
globally will be described and their One Health based strategies
highlighted. The human-animal-wildlife interface resulting in the
transmission of rabies to humans will also be described with a spe-
cial emphasis on the incursion of wildlife rabies in North America.
Finally, strategies for the prevention of over 55,000 human deaths
a year globally from rabies will be assessed from One Health based
perspective and the central role of intradisciplinary approaches
appraised.
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Abstract: HBsAg seroclearance before the age of 50 years of age
is associatedwithdecreased incidenceof hepatocellular carcinoma.
Studies of spontaneous HBsAg seroclearance select special popula-
tion with low viral activities. However HBsAg seroclearance is only
achievable in 8-11% of patients with the current treatment agents
(interferon and nucleoside analogues [NAs]). The pattern of HBsAg
level decline during NA treatment is variable.
In contrast, permanent suppression of HBV DNA levels to below
PCR detectability is achieved in 98-100% of patients on long-term
NAs, irrespective of whether the baseline HBV DNA levels are high
or low. Entecavir and tenofovir are the 2 ﬁrst line choices, with
resistance rates of 1.2% and 0% respectively.
Hepatitis B virus (HBV) covalently closed circular (ccc) DNA,
a minichromosome essential for HBV replication, is supposed to
be resistant to NA treatment. In a pioneering study of 43 subjects
on long-term NAs with continuous viral suppression for a median
of 126 months, patients had three liver biopsies at baseline, after
one year of treatment and at the last follow-up. At the time of
the third biopsy, serum HBV DNA levels were undetectable in all
but one patient. Compared to baseline levels, there was reduc-
tion of HBsAg levels by 71.46%, ihHBV DNA levels by 99.84% and
cccDNA levels by 99.89%, with 49% of patients having undetectable
cccDNA. The median pregenomic RNA level, measured only in the
third biopsy, was 0.021 copies per cell, with 40% of patients having
undetectable pgRNA. Long-term nucleos(t)ide analogue treatment
induced marked depletion of cccDNA in the majority of patients
while serum HBsAg levels, though reduced, were detectable in all
but one patients. Whether cccDNA depletion is sustained and asso-
ciated with better patient outcome requires further study.
There are also several agents currently being investigated. These
agents can be classiﬁed into two main subgroups, direct acting
antiviral agents and host-immune-stimulating agents. The former
group includes HBV entry-to-hepatocyte inhibitors, short interfer-
ingRNA(siRNA), nucleocapsid assembly inhibitors. The latter group
includes therapeutic vaccine and toll-like receptor agonists. These
agents are in Phase I/ II studies. These upcoming agentsmay further
optimize HBV control.
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